Bayer faced tens of thousands of claims linking the weedkiller to cases of non-Hodgkin’s lymphoma. Some of the money is set aside for future cases.
Bayer, the world’s largest seed and pesticide maker, has agreed to pay more than $10 billion to settle tens of thousands of claims in the United States that its popular weedkiller Roundup causes cancer, the company said Wednesday.
The figure includes $1.25 billion to deal with potential future claims from people who used Roundup and may develop the form of cancer known as non-Hodgkin’s lymphoma in the years to come.
“It’s rare that we see a consensual settlement with that many zeros on it,” said Nora Freeman Engstrom, a professor at Stanford University Law School.
Bayer, a German company, inherited the legal morass when it bought Roundup’s manufacturer, Monsanto, for $63 billion in June 2018. It has repeatedly maintained that Roundup is safe.
The settlement, which covers an estimated 95,000 cases, was extraordinarily complex because it includes separate agreements with 25 lead law firms whose clients will receive varying amounts.
Most of the lawsuits filed early on were brought by homeowners and groundskeepers, although they account for only a tiny portion of Roundup’s sales. Farmers are the biggest customers, and many agricultural associations contend glyphosate, the key ingredient in Roundup, is safe and effective.
Bayer still faces at least 25,000 claims from plaintiffs who have not agreed to be part of the settlement.
“This is nothing like the closure they’re trying to imply,” said Fletch Trammell, a Houston-based lawyer who said he represented 5,000 claimants not taking part in the settlement. “It’s like putting out part of a house fire.”
